you have to subscribe, his letter is mostly about market timing the overall market but he does give analysis and recommendations on individual stocks like mdvn
50 is in the cards, nobody likes diarrea, many would rather die than have stage 3 diarrea, in fact you can die from dehidrayshun from the diarrea plus the cramps. this is bad trust me
pbmd didnt do anything at asco. 2 of their people attended as visitors, just like your or i would.
2500 shares of a penny stock? do you even have a margin account?
what did dendreon in was the method of delivery. nobody wants to have thier blood withdrawn wait a week for it to be shipped off centrifuged and then reinjected. people want pills and 1 time shots. any other delivery method will be extremely hard to overcome because of people's mindset.
The Annual Meeting of the American Society of Clinical Oncology (ASCO), held in late May or early June each year, is widely regarded as the premier event globally for researchers and therapeutic developers in the oncology field. In 2014 close to 35,000 people attended the event, more than half of them from outside the United States.
Prima's CEO, Marc Voigt, and CSO & CMO, Professor Frédéric Triebel, will be attending this year's ASCO Annual Meeting in Chicago, which takes place from 29 May to 2 June. Neither Professor Triebel nor his colleagues will be making a formal presentation at the ASCO meeting but, with Mr Voigt, Professor Triebel will be meeting with key opinion leaders in the immuno-oncology field to discuss IMP321 as well as Prima's other programs.
no pbmd is not presenting, but the ceo and cso are visiting on your dime and felt the need to make a pr statement that they are attending asco lol
dont invest in biotechs pre fda approval folks. even then you can lose all. ask dendreon investors.
Could have a steady climb from here to 5ish imo. From there who knows.
Wouldn't surprise me if Luecadia is shorting this company until they hit 50 cents and management has no choice but to sell. This is Luecadia's fastest path to a massive windfall. Always follow the money.
Then the company sells for ~800 million which would have equated to about 7 dollars a share (going off the top of my head). Leucadia gets 90% of the proceeds and longs left with 70 cents a share. I give it 3 months for all this to go down.
Wrong, best case scenario for Leucadia is for the price to tumble to 50 cents (it will soon enough) and have management voluntarily sell the company instead of having to wait until to 2018 to force the sale of the company themselves. A sale should be around 1 billion (being generous but wouldnt be surprised). That means 9.80/share with Leucadia pocketing almost 9 dollars of that and longs left with about 1 dollar a share.
if they wanted to? did you seriously just say that? the cash they have on hand is needed for their regulatory capital requirement. they cease to exist without that capital requirement on hand. that's why they needed the bailout in the first place. good lord. they still owe over 228 million on the loan.
you do realize for the stock to trade at $7.50/share it would be equivelent to trading at $75.00/share before the bailout, yes? the stock price does not represent the value of the company but the value to shareholders. leucadia made it clear on their cc they will not let fxcm escape from the terms of the loan and they are already claiming the proceeds of an estimated sale price of the company on their balance sheet. leucadia gets 90cents of ever dollar of the sale price in case you didnt know. congratulations on losing your money.
Ready Leucadias comments about fxcm during their earnings reports. They have already added the value and proceeds of a forced sale of the company to their balance sheet. Leucadia has no intentions of letting this company pay back the loan and escape even if they could. Smart money exits now. It's all downhill from here. A forced sale at $10 a share will mean $9 goes to Leucadia an $1 to shareholders. Good luck longs. youre going to need it
Show me one floor they sell that isn't a proprietary brand name that they own the trademark for and that isn't made in china. My spot research of all types of flooring they sell has yet to find one.
Nasdaq earnings report charts pulls their earnings from Zacks who is reporting SWKS reported 1.01 vs a target of 1.03. This is a major error. Please get corrected